OGNOGNHealthcare · Drug Manufacturers - General

OGN Stock Forecast: Organon & Co. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$14
−0.14% on the day

The 4 Wall Street analysts covering Organon & Co. hold a median 12-month price target of $9 — -35.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$3.6B
Ticker Nerd rank
92/ 100
Median analyst target
$9.00
Analysts covering
4
Revenue$1.6B−2.3% y/y
Operating income$323.0M
Net income$108.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.1%
1M
+1.1%
YTD
+95.1%
1Y
+96.2%
From 52W high
−0.2%
From 52W low
+144.8%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Organon & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
92/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
99
Accruals
78
Issuance
76
Volatility
70
Quality
70
Growth
59
Revisions
54

Momentum (99): The shares have been drifting up relative to others.

Revisions (54): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26OGNHigh $14.00Median $9.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
0
Buy
3
Hold
1
Sell
$8.00
Low
$9.00
Median
$14.00
High

The green dot is the last close — the median target sits −35.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Apr 2026BNP ParibasDowngradeNeutral$12 → $14
28 Apr 2026Piper SandlerUpgradeNeutral$5.00 → $14
24 Feb 2026BarclaysMaintainsUnderweight—
9 Dec 2025BarclaysInitiatesUnderweight—
11 Nov 2025JP MorganMaintainsUnderweight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
15 May 2025Piper SandlerMaintainsOverweight—
5 May 2025Morgan StanleyMaintainsEqual-Weight—
9 Apr 2025Morgan StanleyMaintainsEqual-Weight—
14 Feb 2025BarclaysMaintainsOverweight—
14 Feb 2025Morgan StanleyMaintainsEqual-Weight—
6 Sept 2024JP MorganDowngradeUnderweight—
6 May 2024Goldman SachsMaintainsNeutral—
3 May 2024Goldman SachsMaintainsNeutral—
29 Apr 2024Piper SandlerMaintainsOverweight—
20 Feb 2024Goldman SachsMaintainsNeutral—
22 Nov 2023Piper SandlerMaintainsOverweight—
3 Nov 2023Goldman SachsDowngradeNeutral—
25 Oct 2023Piper SandlerMaintainsOverweight—
11 Oct 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OGN.

Market Radar

This page is one stock. Monday covers all of them.

OGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Organon & Co. returned +96.2% against +6.9% for the S&P 500, dividends included.

OGN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26OGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.1%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.8×

Cheaper than 49% of US stocks

Price / sales
0.6×

Cheaper than 76% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
6.9×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−1.7%

Higher than 26% of US stocks

Earnings growth (YoY)
2.5%

Higher than 40% of US stocks

Gross margin
54.4%

Higher than 67% of US stocks

Operating margin
19.8%

Higher than 79% of US stocks

Net margin
3.5%

Higher than 53% of US stocks

Returns & dividend
Return on equity
20.3%

Higher than 81% of US stocks

Return on assets
5.6%

Higher than 79% of US stocks

Dividend yield
0.6%

Higher than 9% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Organon & Co. has a market value of $3.6B and an enterprise value of $10.7B.

  • Revenue in the twelve months to 30 June 2026: $6.1B. The latest quarter shrank 2.3% year on year.

  • Net income over the same four quarters: $209.0M, a 3.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.77.

  • Free cash flow in the twelve months to 30 June 2026: $434.0M, after $170.0M of capital spending.

  • Organon & Co. spent $18.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 262.6M.

  • Trailing P/E: 17.8×; forward P/E: 3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.58%, paying out 10% of earnings.

  • Organon & Co. employs 10,000 people — $613K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

OGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
OGNOrganon & Co.$3.6B92
ZOARZoar Ltd.$608.4M18
BIIBBiogen, Inc.$36.9B79
NVSTEnvista Holdings Corp.*$3.7B96
CDNACareDx, Inc.*$3.6B92
TARSTarsus Pharmaceuticals, Inc.*$3.6B72
CRSPCRISPR Therapeutics AG*$3.8B33

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Take a look at OGN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Organon & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OGN

What is the OGN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Organon & Co. have a median 12-month price target of $9, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OGN stock a buy right now?

Of the 4 analysts covering Organon & Co., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Organon & Co. 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGN?

As at 21 Nov 2026, Organon & Co. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will OGN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies -35.2% from the last close, and Ticker Nerd's factor model ranks Organon & Co. 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OGN stock forecast for 2030?

No analyst covering Organon & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.

How has OGN stock performed over the past year?

Organon & Co. returned +96.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organon & Co. do?

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine.

Company

About Organon & Co.

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.

CEO Mr. Kevin Ali · 10,000 employees · United States · https://www.organon.com